Vanda Pharmaceuticals Inc
VNDA4.400USD
-0.010-0.23%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
260.02MMarket Cap
LossP/E TTM
More Details of Vanda Pharmaceuticals Inc Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Vanda Pharmaceuticals Inc Info
Ticker SymbolVNDA
Company nameVanda Pharmaceuticals Inc
IPO dateApr 12, 2006
CEODr. Mihael Hristos Polymeropoulos, M.D.
Number of employees368
Security typeOrdinary Share
Fiscal year-endApr 12
AddressSuite 300E
CityWASHINGTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code20037
Phone12027343400
Websitehttps://www.vandapharma.com/
Ticker SymbolVNDA
IPO dateApr 12, 2006
CEODr. Mihael Hristos Polymeropoulos, M.D.
Company Executives of Vanda Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+0.43%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
Dr. Stephen Ray Mitchell, M.D.
Dr. Stephen Ray Mitchell, M.D.
Independent Director
Independent Director
97.08K
+116.43%
Mr. Timothy I. Williams
Mr. Timothy I. Williams
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Ms. Phaedra S. Chrousos
Ms. Phaedra S. Chrousos
Independent Director
Independent Director
--
--
Mr. Joakim (Kim) Wijkstrom
Mr. Joakim (Kim) Wijkstrom
Senior Vice President, Chief Marketing Officer
Senior Vice President, Chief Marketing Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+0.43%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Fanapt
29.29M
55.70%
Hetlioz
16.19M
30.79%
PONVORY
7.10M
13.51%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Fanapt
29.29M
55.70%
Hetlioz
16.19M
30.79%
PONVORY
7.10M
13.51%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.13%
The Vanguard Group, Inc.
5.99%
Renaissance Technologies LLC
5.83%
Millennium Management LLC
5.28%
Dimensional Fund Advisors, L.P.
4.38%
Other
68.39%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.13%
The Vanguard Group, Inc.
5.99%
Renaissance Technologies LLC
5.83%
Millennium Management LLC
5.28%
Dimensional Fund Advisors, L.P.
4.38%
Other
68.39%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.57%
Investment Advisor/Hedge Fund
27.14%
Hedge Fund
19.34%
Individual Investor
7.19%
Research Firm
3.40%
Pension Fund
0.72%
Bank and Trust
0.20%
Sovereign Wealth Fund
0.19%
Venture Capital
0.05%
Other
14.18%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
373
46.47M
78.64%
-9.95M
2025Q2
417
50.75M
85.90%
-11.31M
2025Q1
426
48.51M
82.37%
-12.27M
2024Q4
444
46.48M
79.71%
-15.23M
2024Q3
446
47.42M
81.36%
-14.93M
2024Q2
445
46.99M
80.73%
-18.42M
2024Q1
434
53.50M
92.97%
-11.41M
2023Q4
445
55.38M
96.27%
-9.21M
2023Q3
446
56.79M
98.75%
-12.15M
2023Q2
434
60.42M
105.19%
-10.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.99M
10.13%
-31.47K
-0.52%
Jun 30, 2025
The Vanguard Group, Inc.
3.54M
5.99%
+46.84K
+1.34%
Jun 30, 2025
Renaissance Technologies LLC
3.45M
5.83%
-118.97K
-3.34%
Jun 30, 2025
Millennium Management LLC
3.12M
5.28%
+980.75K
+45.84%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.59M
4.38%
+46.08K
+1.81%
Jun 30, 2025
BlackRock Financial Management, Inc.
2.43M
4.12%
+286.64K
+13.35%
Jun 30, 2025
Tang Capital Management, LLC
2.35M
3.98%
--
--
Jun 30, 2025
Polymeropoulos (Mihael Hristos)
2.34M
3.95%
+10.00K
+0.43%
Aug 07, 2025
Acadian Asset Management LLC
1.73M
2.93%
-155.16K
-8.22%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.69M
2.86%
+78.00K
+4.83%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.51%
iShares Neuroscience and Healthcare ETF
0.49%
ALPS Medical Breakthroughs ETF
0.17%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.13%
Federated Hermes MDT Small Cap Core ETF
0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.05%
Franklin US Small Cap Multifactor Index ETF
0.04%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.51%
iShares Neuroscience and Healthcare ETF
Proportion0.49%
ALPS Medical Breakthroughs ETF
Proportion0.17%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.13%
Federated Hermes MDT Small Cap Core ETF
Proportion0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.05%
Franklin US Small Cap Multifactor Index ETF
Proportion0.04%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
